https://de.marketscreener.com/kurs/aktie/EDESA-BIOTECH-INC-59637813/news/Edesa-Biotech-und-FDA-einigen-sich-auf-primaren-Endpunkt-fur-Phase-3-Studie-mit-ARDS-Medikament-43261320/?utm_source=telegram&utm_medium=social&utm_campaign=share